We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03664830
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : February 21, 2022
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
The objective of this study is to investigate if up to two injections of plerixafor represent a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem progenitor cells (HSPC) for autologous hematopoietic cell transplantation (HCT) in sickle cell disease (SCD) patients

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Plerixafor Phase 1

Detailed Description:
Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for sickle cell disease (SCD) patients but its use is significantly limited by the lack of compatible donors. Gene therapy using autologous hematopoietic stem cell (HSC) transplantation represents an alternative approach but requires the collection of significant numbers of cells. Severe adverse events have been observed in SCD patients after mobilization using the standard agent granulocyte colony-stimulating factor (G-CSF), and bone marrow harvesting is also associated with side effects. The use of a single administration of plerixafor has been suggested as an alternative mobilization strategy in SCD but may not mobilize sufficient number of HSC. In this study, our primary objective is to assess if up to two injections of plerixafor (starting dose level: 240 µg/kg/dose) are safe in SCD patients and can recruit enough blood stem cells needed for future gene therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Each SCD research participant will receive up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
Actual Study Start Date : September 19, 2018
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Plerixafor

Arm Intervention/treatment
Experimental: Plerixafor
Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
Drug: Plerixafor
Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)

Primary Outcome Measures :
  1. Toxicities [ Time Frame: 120 hours (5 days) from the last injection of plerixafor ]
    Scored using the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 4.03

Secondary Outcome Measures :
  1. Stem cell mobilization feasibility [ Time Frame: 6 hours after the first injection of plerixafor. ]
    Assessed by measuring the number of mobilized CD34+ cells/µL of peripheral blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Weight between 50 and 120 kg;
  • Karnofsky performance status (KPS) ≥70%;
  • Confirmed diagnosis of sickle cell disease with βS/βS or βS/β0 or βS/β+ genotype;
  • Must have had one or more of the following events in the 2 year period preceding enrollment:

    • History of ≥2 severe vaso-occlusive pain crises (VOC) (or at least two episodes in the year preceding the setting up of regular transfusion protocol). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility.
    • History of ≥1 episodes of acute chest syndrome despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea)
    • Clinically significant neurological event (stroke) or any neurological deficit lasting 24 hours. A stroke is defined as a sudden neurological change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes.
    • Prior treatment with regular RBC transfusion therapy, defined as receiving ≥8 transfusions per year for >1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
    • Osteonecrosis of two or more joints;
    • Anti-erythrocyte alloimmunization (>2 antibodies);
    • Presence of sickle cell cardiomyopathy documented by Doppler echocardiography;
    • Presence of any significant cerebral abnormality such as stenosis or occlusions on magnetic resonance imaging (MRA)
  • Meet current eligibility requirements for donation for mobilization at the COH DAC;
  • Adequate renal function: defined as a creatinine estimated FDR (eGFR) of ≥60 ml/min;
  • Adequate liver function: defined by a serum conjugated (direct) bilirubin <2.5x upper limit of normal (ULN) for age; AST and ALT <5x ULN for age as per laboratory;
  • Adequate cardiac function: defined as left ventricular ejection fraction >50%;
  • Adequate hematologic parameters: WBC ≥2.5 x 10^9/L; platelet count ≥120 x10^9/L; hemoglobin >8 g/dL;
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry.

Exclusion Criteria:

  • Diagnosed with alpha thalassemia (two or more gene deletions or any α-globin structural variants);
  • Seropositivity for HIV-1/2 (Human Immunodeficiency Virus) or HTLV-1/2(Human T-Lymphotropic Virus);
  • Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to treatment. Participants with fever should await resolution of symptoms before starting the treatment;
  • Any clinically significant active infection which, in the opinion of the investigator, would require significant medical intervention;
  • Abnormal pulmonary function tests (adults with mild or moderate obstruction or restriction or diffusion defects are eligible, per Investigator discretion).
  • History of pulmonary hypertension, proven by cardiac catheterization;
  • History of malignancy or immunodeficiency disorder, (i.e., subjects with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma or cutaneous squamous cell carcinoma;
  • Participation in any study with an investigational agent or medical device within 90 days of screening;
  • Major surgery in the past 30 days;
  • Prior receipt of any gene transfer product;
  • Bone marrow harvest in the past year;
  • Known myelodysplasia of the bone marrow or abnormal bone marrow cytogenesis;
  • Known hypersensitivity to plerixafor or any excipient contained in Mozobil;
  • G-CSF or plerixafor medication within 4 weeks of treatment;
  • Pregnant or nursing women;
  • Any condition or chronic physical, neurological, or mental illness, which in the opinion of the investigator, makes participation ill advised.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03664830

Layout table for location contacts
Contact: Joseph Rosenthal, MD 626-256-4673 ext 88442 jrosenthal@coh.org

Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Joseph Rosenthal, MD    626-256-4673 ext 88442    jrosenthal@coh.org   
Principal Investigator: Joseph Rosenthal, MD         
Sponsors and Collaborators
City of Hope Medical Center
Layout table for investigator information
Principal Investigator: Joseph Rosenthal, MD City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03664830    
Other Study ID Numbers: 17426
First Posted: September 11, 2018    Key Record Dates
Last Update Posted: February 21, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by City of Hope Medical Center:
sickle cell disease
hematopoietic stem cell
gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents